Introduction Automated insulin delivery systems (AID) are the preferred treatment modality for type 1 diabetes (T1D) because use improves time in range (TIR), reduces hypoglycemia, and helps to ease the burden of diabetes (1, 2). In the last year, the results of clinical trials demonstrating the efficacy of AID in individuals with type 2 diabetes (T2D) have further expanded indications for AID use (1, 3, 4). However, AID remains underutilized (5).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Brynn E. Marks
Endpoints for clinical trials in type 1 diabetes drug development
Type 1 diabetes is characterised by substantial disease heterogeneity which influences rates of progression during presymptomatic stages, age at clinical onset, and residual β-cell function at the time of detectable autoimmunity. This heterogeneity poses challenges for disease staging and calls attention to the need for new surrogate endpoints in trials assessing disease-modifying therapies that better quantify and longitudinally track β-cell function.
Tubeless hybrid closed-loop system boosts time in range for youths with type 1 diabetes
You've successfully added Endocrinology: Diabetes to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Endocrine Complications of Cystic Fibrosis
Kwong E. Desai S. Chong L. et al. The impact of cystic fibrosis-related diabetes on health-related quality of life. J Cystic Fibrosis. 2019; : 7-9 Moran A. Brunzell C. Cohen R.C. et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care.
Patterns of Continuous Glucose Monitor Use in Young Children Throughout the First 18 Months Following Type 1 Diabetes Diagnosis
Introduction Continuous glucose monitor (CGM) use among youth is associated with better glycemic control1 as well as parent psychoscial functioning.2 The 2021 American Diabetes Association (ADA) guidelines state that CGM is the preferred method for glucose monitoring in people with type 1 diabetes (T1D).3 Not surprisingly, there has been an increase in CGM use over the last few years, particularly among children ≤6 years.4 Among youth with T1D, glycemic control during the first year post-T1D...
New-onset pediatric type 2 diabetes cases increase 182% during first year of COVID-19
June 26, 2021 3 min read Save Source/Disclosures Published by: Source: Marks B. 15-OR. Presented at: American Diabetes Association Scientific Sessions; June 25-29, 2021 (virtual meeting). Disclosures: Marks reports she has received funding from Tandem Diabetes Care and supplies from Dexcom. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Brynn E.
Contact Brynn E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack